Company News: Johnson & Johnson and Basilea Pharmaceutica AG

Share this article:
The FDA told Johnson & Johnson that additional clinical studies are required before the agency will consider approving antibiotic ceftobiprole. It's the latest setback for the J&J and its development partner, Swiss biotech Basilea Pharmaceutica AG, over the anti-infective, whose US approval for treating complicated skin and skin structure infections (cSSSI) has been pending since May 2007. “We're going to meet with [FDA] to talk about the path forward,” said a J&J spokesman. “That could include new trials, but it hasn't been determined yet.” J&J received an approvable letter for ceftobiprole in March 2008 and an initial complete response letter the following November, in which the agency asked that the firm conduct audits of its trial sites. J&J, which licensed ceftobiprole in 2005 from Basilea, said it responded to both letters. Basilea issued its own statement on the delay, saying the FDA warned J&J earlier this year that its US partner had “failed to adequately monitor” investigator conduct in the studies. Dr. Anthony Man, Basilea CEO, said his firm is committed to making the drug more widely available. Regulatory review in the EU is ongoing, with a decision expected in early 2010. Basilea also said it took the case to arbitration last February, claiming J&J caused the delay and seeking “significant” damages.
Share this article:

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.